COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) [NG200], NICE (published 29th July 2021)

This guideline covers vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome which has been reported in rare cases after COVID-19 vaccination. VITT may also be called vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or thrombotic thrombocytopenic syndrome (TTS). Because VITT is a new condition, there is limited evidence available to inform clinical management, identification and management of the condition is evolving quickly as the case definition becomes clearer. This guideline was produced to support clinicians to diagnose and manage this newly recognised syndrome.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news